Remove 2019 Remove Competition Remove Prescription
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.

article thumbnail

Insulin prices demonstrate pharma’s greed

World of DTC Marketing

According to the Mayo Clinic “The 3 main reasons cited by pharmaceutical companies for the high cost of new prescription drugs do not apply to insulin. 9 One vial of Humalog (insulin lispro), which used to cost $21 in 1999, costs $332 in 2019, reflecting a price increase of more than 1000%. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

 The US accounts for more than 40% of all health spending.

World of DTC Marketing

Hospitals, physicians, and clinical care made up more than half of the total healthcare spending in 2019. The lack of choice limits competition, which can drive prices higher. According to KFF, “ the cost of health care often prevents people from getting needed care or filling prescriptions. Half of U.S.

Insurance 154
article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Via Axios “The 10 highest-selling drugs in the U.S.

Pharma 241
article thumbnail

Novartis said to be eyeing sale of ophthalmology, respiratory units

pharmaphorum

Novartis completed the spin-out of Alcon in 2019, separating products like contact lenses and over-the-counter eyedrops from its prescription eye medicines, headed by age-related macular degeneration (AMD) blockbuster Lucentis (ranibizumab), which is partnered with Roche. billion in the first nine months of this year.

Sales 124
article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.” billion (around $4 billion) in revenue to the government – 26.5% VPAS tax on top. .

Pharma 72
article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

The landscape is highly competitive with new prescription medications launching worldwide each year. Early shaping of the label during clinical trial design, risk mitigation, and avoiding approval delays are crucial for seizing a competitive advantage.